Phage Therapy Center
Bacteriophage Therapy for Patients Across the Globe
HOME CONTACT US LOGIN
Language Translation

About Our Company
About Us, What We Do
Our History
Our Mission
Our Management
Phage Therapy
Phage Therapy Center Clinics
Become A Patient
News
Web Links
Patient
Physicians
 

Pseudomonas aeruginosa, an increasingly prevalent opportunistic human pathogen, is the most common gram-negative bacterium found in nosocomial (hospital-acquired) infections. P. aeruginosa is responsible for 16% of nosocomial pneumonia cases, 12% of hospital-acquired urinary tract infections, 8% of surgical wound infections, and 10% of bloodstream infections. Immunocompromised patients, such as neutropenic cancer and bone marrow transplant patients, are particularly susceptible to opportunistic infections. In this group of patients, P. aeruginosa is responsible for pneumonia and septicemia with attributable deaths reaching 30%. P. aeruginosa is also one of the most common and lethal pathogens responsible for ventilator-associated pneumonia in intubated patients, with directly attributable death rates reaching 38%. In burn patients, P. aeruginosa bacteremia has declined as a result of better wound treatment and dietary changes (removal of raw vegetables, which can be contaminated with P. aeruginosa, from the diet). However, P. aeruginosa outbreaks in burn units are still associated with high (60%) death rates. In the expanding AIDS population, P. aeruginosa bacteremia is associated with 50% of deaths. Cystic fibrosis (CF) patients are characteristically susceptible to chronic infection by P. aeruginosa, which is responsible for high rates of illness and death in this population. The capacity of P. aeruginosa to produce such diverse, often overwhelming infections is due to an arsenal of virulence factors. Many extracellular virulence factors secreted by P. aeruginosa have been shown to be controlled by a complex regulatory circuit involving cell-to-cell signaling systems that allow the bacteria to produce these factors in a coordinated, cell-density–dependent manner. In this article we describe major virulence factors of P. aeruginosa and the possible involvement of cell-to-cell signaling in the pathogenesis of acute P. aeruginosa infection. We also summarize data suggesting that these regulatory systems could be exploited for the design of therapeutic interventions.

Proteases are assumed to play a major role during acute P. aeruginosa infection. P. aeruginosa produces several proteases including LasB elastase, LasA elastase, and alkaline protease. The role of alkaline protease in tissue invasion and systemic infections is unclear; however, its role in corneal infections may be substantial. The ability of P. aeruginosa to destroy the protein elastin is a major virulence determinant during acute infection. Elastin is a major part of human lung tissue and is responsible for lung expansion and contraction. Moreover, elastin is an important component of blood vessels, which rely on it for their resilience. The concerted activity of two enzymes, LasB elastase and LasA elastase, is responsible for elastolytic activity. Elastolytic activity is believed to destroy elastin-containing human lung tissue and cause the pulmonary hemorrhages of invasive P. aeruginosa infections. LasB elastase is a zinc metalloprotease that acts on a number of proteins including elastin. LasB elastase is highly efficient, with a proteolytic activity approximately 10 times that of P. aeruginosa alkaline protease and an activity toward casein approximately four times that of trypsin. The LasA elastase is a serine protease that acts synergistically with LasB elastase to degrade elastin. LasA elastase nicks elastin, rendering it sensitive to degradation by other proteases such as LasB elastase, alkaline protease, and neutrophil elastase. Both LasB elastase and LasA elastase have been found in the sputum of CF patients during pulmonary exacerbation. However, the role of LasB elastase in tissue destruction during the chronic phase of CF is less clear. It has been postulated that during this phase, antibodies present in high titers neutralize LasB elastase, and elastin damaged by minute amounts of LasA is degraded mostly by neutrophil elastase. LasB elastase degrades not only elastin but also fibrin and collagen. It can inactivate substances such as human immunoglobulins G and A, airway lysozyme, complement components, and substances involved in protecting the respiratory tract against proteases such as a-1-proteinase inhibitor and bronchial mucus proteinase inhibitor. Therefore, LasB elastase not only destroys tissue components but also interferes with host defense mechanisms. Studies in animal models show that mutants defective in LasB elastase production are less virulent than their parent strains, which supports the role of LasB elastase as a virulence factor.

Return to: Medical Conditions that We Treat